metronidazole has been researched along with Vertigo in 3 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Vertigo: An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mostly, metronidazole is a tolerable drug but rarely presents serious adverse effects on the nervous system." | 2.49 | A rare adverse effect of metronidazole: nervous system symptoms. ( Kafadar, I; Klç, BA; Moustafa, F; Yalçın, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kafadar, I | 1 |
| Moustafa, F | 1 |
| Yalçın, K | 1 |
| Klç, BA | 1 |
| Chen, PS | 1 |
| Huang, JK | 1 |
| Cheng, SJ | 1 |
| Lin, HC | 1 |
| Naoemar, SA | 1 |
| Rukmono, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis (Pilot Study)[NCT02201186] | Phase 2 | 10 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metronidazole and Vertigo
| Article | Year |
|---|---|
A rare adverse effect of metronidazole: nervous system symptoms.
Topics: Anti-Infective Agents; Ataxia; Child, Preschool; Convalescence; Dizziness; Dysentery, Amebic; Headac | 2013 |
1 trial available for metronidazole and Vertigo
| Article | Year |
|---|---|
Clinical trial of Ro7-0207, a nitroimidazole derivative in amoebic dysentery.
Topics: 1-Propanol; Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; | 1973 |
1 other study available for metronidazole and Vertigo
| Article | Year |
|---|---|
Metronidazole-induced vertigo.
Topics: Anti-Infective Agents; Female; Humans; Magnetic Resonance Imaging; Metronidazole; Middle Aged; Verti | 2013 |